Oseltamivir

Tamiflu

Bibliografia - Quali fonti bibliografiche per Oseltamivir?

1. Afssaps, Modification des caracteristiques du produit Tamiflu, 2007, www.affsaps.sante.fr


2. Aoki F.Y. et al., J. of Antimicrobial Chemotherapy, 2003, 51, 123.


3. CDC, Health Advisory, 2008. Disponibile sul sito: www.cdc.gov


4. CDC, Influenza activity, United States and Worldwide, 2007-2008 season, MMWR, 2008a, 57, 692.


5. CDC, Weekly Report, Influenza Summary Update 2008-2009 Influenza Season Week 53 ending, 2009. Disponibile sul sito: www.cdc.gov/flu/weeklyarchives2008-2009/weekly53.htm


6. Dutkowski R. et al., Drug Safety, 2003, 26, 787.


7. EMEA, EPAR, Scientific discussion, 2006, www.emea.eu.int/humanodocs/Humans/EPAR/tamiflu/tamiflu.htm


8. EMEA, Procedural steps taken and scientific information after the authorisation. Tamiflu, 2007, www.emea.europa.eu


9. FDA Advisory Committee, 2005, www.fdaadvisorycommittee.com


10. Hatakeyama S. et al., JAMA, 2007, 297, 1435.


11. Hayden F.G. et al., NEJM, 1999, 341, 1336.


12. Hayden F.G. et al., J. Infect. Dis., 2004, 189, 440.


13. Hayden F.G. et al., Antivir. Ther., 2005, 10, 873.


14. He G. et al., Am. Assoc. Pharmac. Sci., Southeast Regional Meet., 1999, 21 giugno, Durham (NC), poster.


15. He G. et al., Clin. Pharmacokinet., 1999a, 37, 471.


16. He G. et al., 9th ECCMID, 1999b, 21-24 marzo, Berlino.


17. Hien T.T. et al., NEJM, 2004, 350, 1179.


18. Hill G. et al., Drug Metab. Dispos., 2002, 30, 13.


19. Kaiser L. et al., Arch. Inter. Med., 2000, 160, 3234.


20. Kaiser L. et al., Arch. Inter. Med., 2003, 163, 1667.


21. Kawai N. et al., Clin. Infect. Dis., 2006, 43, 439.


22. Kiso M. et al., Lancet, 2004, 364, 759.


23. Ishizaka T. et al., Chem. Pharm. Bull. 2004, 52, 943.


24. Ison M.G. et al, J. Infect. Dis., 2006, 193, 760.


25. Johnston S.L. et al., Pediatr. Infect. Dis. J., 2005, 24, 225.


26. Lackenby A. et al., Euro. Surveill, 2008, 13, 8026.


27. Le Q.M. et al., Nature, 2005, 436, 1108.


28. Lee N. et al., Antivir. Ther., 2007, 12, 501.


29. Leneva I.A. et al., Antiviral. Res., 2000, 48, 101.


30. Li L.Y. et al., Chin. Med. J., 2003, 116, 44.


31. Massarella J.W. et al., J. Clin. Pharmacol., 2000, 40 (8), 836.


32. McClellan K., Perry CM., Drugs, 2001, 61 (2), 263.


33. McGeer A. et al., Clin. Infect. Dis., 2007, 45, 1568.


34. Mendel D.B. et al., Antimicrob. Agents Chemother., 1998, 42, 640.


35. Mendel D.B., Sidwell R.W., Drug. Resist. Updat., 1998, 1(3), 184.


36. Moscona A., McKimm-Breschkin J., JAMA, 2007, 297, 1492.


37. Neuraminidase Inhibitor Susceptibility Network, Wkly Epidemil. Rec., 2007, 17, 149.


38. Nicholson K.G. et al., Lancet, 2000, 355, 1845.


39. Nordstrom B.L. et al., Curr. Med. Res. Opin., 2005, 21, 761.


40. Ong A.K., Hayden F.G., J. Infect. Dis., 2007, 196, 181.


41. Peters Jr. P.H. et al., J. Am. Geriatr. Soc., 2001, 49, 1025.


42. Prescrire Editorial Staff, Prescrire Int., 2006, 26, 432.


43. Sheu T.G. et al., Antimicrob. Agents Chemoter., 2008, 52, 3284.


44. Sidwell R.W. et al., Antiviral Res., 1998, 37, 107.


45. Toovey S. et al., Drug Saf., 2008, 31, 1097.


46. Torre F. et al., Am. J. Respir. Crit. Care Med., 2000, 161 (3 Pt 2 Suppl.), A 720.


47. Treanor J.J. et al., JAMA, 2000, 283, 1016.


48. Van der Vries E. et al., NEJM, 2008, 359, 1074.


49. Welliver R. et al., JAMA, 2001, 285, 748.


50. Whitley R.J. et al., Pediatr. Infect. Dis. J., 2001, 20, 127.


51. WHO consultation on human influenza H5N1, N. Engl. J. Med., 2005, 353, 1374.


52. Winther B. et al., ICAAC, 2000, 17-20 settembre, Toronto (poster).


53. Zaug M. et al., Clin. Microbiol. Infect., 2000, 6 Suppl. 1, 139 (Abst.).


54. Zaug M. et al., ECCMID, 2000a, 28-31 maggio, Stoccolma.